source
- Compliance worries keep AI adoption in drug manufacturing low, survey findsA new survey of more than 400 research and manufacturing professionals shows that over 90% of drugmakers have not committed to expanding AI use in regulated drug production. While AI is widely em…
- ArriVent’s phase 3 EGFR inhibitor trial misses primary endpoint, shares plunge 57%ArriVent BioPharma reported results from its phase 3 Furvent trial, which evaluated firmonertinib, a brain-penetrant EGFR inhibitor, in patients with exon 20 insertion-mutated non-small cell lung c…